Fibulin-7 (Fbln7) is one of the latest members of the Fibulin family of secreted glycoproteins. Previous reports have shown that a C-terminal fragment of Fbln7 (Fbln7-C) have antiangiogenic activity and could modulate migration and functions of inflammatory monocytes and macrophages. In this study, we have investigated the potential anti-cancer activity of Fbln7C. Our in vitro studies demonstrate that Fbln7-C could inhibit the proliferation of MDA-MB-231, MCF-7 and PANC-1 cell lines. Similarly, Fbln7-C also reduced the growth of tumors in a 4T1 cell induced murine mammary tumor in a dose dependent manner. Additionally, detailed phenotypic analysis of tumor associated macrophages (TAM) using various surface markers revealed that TAMs were arrested in an anti-tumorigenic M1 type phenotype (MHChiLy6ClowCD206low) in animals treated with Fbln7C compared to control group. In line with the in vitro results, Fbln7C inhibited the polarization of human monocyte derived macrophages into tumor supernatant induced TAMs which retained their inflammatory M1 like phenotype even after removal of Fbln7C from culture. The above observation indicates that Fbln7-C could be used as supportive immunomodulatory therapeutic for cancers.